Bolt Biotherapeutics


ATLANTA, GA – – (Globe Newswire – July 3, 2024) – – A shareholder class action lawsuit has been filed against officers of Bolt Biotherapeutics, Inc. (“Bolt” or the “Company”) (NASDAQ: BOLT). The lawsuit alleges that Defendants made materially false and misleading statements and/or failed to disclose material adverse information, regarding the Company’s business, operations, and prospects, including allegations that: (i) Bolt’s product, BDC-1001, was less effective than the Company had represented to investors and was in fact unlikely to meet its pre-defined success criteria; (ii) accordingly, Defendants overstated the clinical and/or commercial prospects of Bolt’s product pipeline, on which the Company primarily relies to sustain its business model; and (iii) all of the foregoing subjected Bolt to a heightened risk of disruptive leadership transitions and substantial workforce reduction.

If you bought shares of Bolt between February 5, 2021 and May 14, 2024, and you suffered a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at, by toll-free telephone at (888) 508-6832 or you may visit the firm’s website at to learn more.

The deadline to ask the court to be appointed lead plaintiff in the case is September 3, 2024.

Registration Deadline

Lead Plaintiff Deadline Has Passed

September 3, 2024

Submit Your Information

Shares Purchased(Required)
Date of Shares Purchased
Number of Shares Acquired
Acquisition Price Per Share
Shares Sold
Date of Shares Sold
Number of Shares Sold
Selling Price Per Share